116 results
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
16 Feb 22
Other Events
8:31am
the significant unmet need for these patients and CYNK-101’s potential in a new first-line treatment strategy,” said Robert Hariri, M.D., Ph.D … a multipronged strategy of our NK cells and activated T cells through check point inhibition to potentially enhance overall outcomes achieved
8-K
CELU
Celularity Inc - Ordinary Shares
6 Oct 22
Departure of Directors or Certain Officers
4:08pm
of Corporate Strategy & Operations at Kite Pharma, Inc., which he first joined in September 2016 and held several executive roles in corporate … Group) from 2008 through September 2016 in the areas of finance, strategy, supply chain operations and alliance management. Dr. Glover holds a Ph.D
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
22 Jul 21
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
4:13pm
programs. With his significant expertise in operational management and business strategy, Celularity aims more rapidly advance its clinical … Celularity’s therapeutic candidates and scale production; Celularity’s ability to meet certain milestones; changes in Celularity’s strategy, future operations
425
CELU
Celularity Inc - Ordinary Shares
15 Jun 21
Business combination disclosure
12:00am
of these clinical programs and understand our strategy in driving them to registration shortly. And then a third important factor I’d like you to consider … representing multiple shots on goal and a clinical development strategy that can be readily extended to additional indications and we’ll be—and Dr. Pecora
424B3
CELU
Celularity Inc - Ordinary Shares
16 Feb 22
Prospectus supplement
8:36am
-101’s potential in a new first-line treatment strategy,” said Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity … in a range of indications. In our Phase 1/2a clinical trial of CYNK-101, we are excited to explore a multipronged strategy of our NK cells and activated T
UPLOAD
2lvjuc8kmfw
15 Jun 21
Letter from SEC
12:00am
UPLOAD
qli lpw41ej5ar
6 May 21
Letter from SEC
12:00am
425
amnkj95
1 Jul 21
Business combination disclosure
5:09pm
UPLOAD
ors2d3
14 Apr 21
Letter from SEC
12:00am
CORRESP
nlu 642zd7mtvzs
21 Jun 21
Correspondence with SEC
12:00am
425
729vfq4r1lk
21 Apr 21
Business combination disclosure
4:19pm
CORRESP
qyextwmartvpigq
4 Jun 21
Correspondence with SEC
12:00am
425
kp4bqbpj6xy4jes
1 Feb 21
Business combination disclosure
5:22pm
425
1g466m49s5zi2
20 Apr 21
Business combination disclosure
6:14am
8-K
EX-99.1
37lh6x81
14 May 21
GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal
5:09pm
UPLOAD
4i1jf2v1ys6rud4a
22 Feb 21
Letter from SEC
12:00am
425
EX-99.1
9o71ln5u3m7
14 May 21
Business combination disclosure
5:07pm
8-K
EX-99.1
sduap
12 Nov 21
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
4:19pm
8-K
ud3 qityusqcmxyo
30 Apr 21
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
10:45am